NCT05184088CompletedPhase 3
An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL Amyloidosis
Lantheus Germany GmbH26 sites in 4 countries244 target enrollmentStarted: January 13, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Lantheus Germany GmbH
- Enrollment
- 244
- Locations
- 26
- Primary Endpoint
- Sensitivity and specificity of the visual assessment of [18F]florbetaben PET images for the diagnosis of cardiac AL amyloidosis.
Study Overview
Brief Summary
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.
Detailed Description
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis or with a putative diagnosis of cardiac amyloidosis but with remaining diagnostic uncertainty (e.g., unclear etiology or cardiac manifestation) or patients with diagnosis of amyloidosis but unclear cardiac involvement.
The diagnostic efficacy of the visual and quantitative assessments of [18F]florbetaben PET images for diagnosis of cardiac AL Amyloidosis will be determined by comparison to the standard of truth (SoT) obtained through standard of care clinical diagnosis.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Males and females age ≥18 years
- •Able to understand, sign and date written informed consent
- •Written informed consent must be obtained before any study procedures are performed
- •Subjects being considered for a possible diagnosis of cardiac amyloidosis by
- •1. One of the following conditions:
- •Established systemic amyloidosis without proven cardiac involvement,
- •Known plasma cell dyscrasia (MGUS, multiple myeloma),
- •Pathological free light chain levels in urine or serum,
- •Presence of heart failure with preserved ejection fraction
- •2. AND one of the following parameters, indicative of cardiac manifestation:
- •Mean (left ventricular (LV) wall + septum) thickness >12mm as measured by echocardiography or CMR in absence of other known cause of left ventricular hypertrophy (LVH),
- •NT-proBNP >335 ng/L (in case a value for NT-proBNP is not available, BNP > 81ng/L may be used instead)
- •Planned diagnostic procedure to establish diagnosis and cardiac involvement (e.g., endomyocardial biopsy or extracardiac biopsy in conjunction with cardiac magnetic resonance imaging/echocardiography or bone scintigraphy)
- •Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of child-bearing potential, they must commit to use of a highly effective contraceptive measure for at least one week following the PET scan (including combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilaterial tubal occlusion, vasectomised parner or secual abstinence).
- •Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following the PET scan (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilaterial tubal occlusion, male subjects with vasectomy or sexual abstinence)
- •Male subjects must commit to not donate sperm for a minimum of 90 days after the PET scan
Exclusion Criteria
- •Any known allergic reactions or hypersensitivity towards any compound of the study drug
- •Severe hepatic impairment (AST/ALT >5 x ULN; bilirubin >3 x ULN)
- •Inability to lay flat for up to 60 min
- •Pregnant, lactating or breastfeeding
- •Unwilling and/or unable to cooperate with study procedures
- •Having been administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study
Arms & Interventions
Patients with suspected cardiac amyloidosis
Experimental
After enrolment, patients will be subjected to diagnostic procedures according to standard of care to resolve diagnostic uncertainties and to clarify possible cardiac involvement. The results of the clinical work-up will be used a standard of truth, i.e. patients with initially suspected cardiac amyloidosis that where subsequently clinically diagnosed with cardiac AL Amyloidosis, cardiac ATTR Amyloidosis, other cardiac Amyloidosis or non cardiac amyloidosis.
Intervention: [18F]florbetaben (Drug)
Outcomes
Primary Outcomes
Sensitivity and specificity of the visual assessment of [18F]florbetaben PET images for the diagnosis of cardiac AL amyloidosis.
Time Frame: Up to 12 weeks
The results from the visual assessment of \[18F\]florbetaben PET images are compared to the clinical diagnosis established through histological verification of the presence or absence of AL amyloidosis with cardiac involvement determined either through endomyocardial biopsy or through extracardiac biopsy in conjunction with typical CMR or echocardiography imaging features as the standard of truth.
Secondary Outcomes
- Sensitivity and specificity of [18F]florbetaben PET for the diagnosis of cardiac AL amyloidosis using quantification.(Up to 12 weeks)
- Correlation of quantitative [18F]florbetaben PET results with left ventricular ejection fraction (LV EF) and left ventricular mass (LV mass).(Up to 12 weeks)
- Correlation of quantitative [18F]florbetaben PET results with AL CA stage I - IV based on FLC-diff, cTnT and NT-proBNP levels.(Up to 12 weeks)
- Number of adverse events(Up to 17 days after imaging visit)
- Impact of PET imaging (AL-CA/non AL-CA) on diagnostic thinking and patient management will be assessed with physician's questionnaires before and after the diagnostic work-up, and after receipt of the PET results.(Up to 14 weeks)
Investigators
Study Sites (26)
Loading locations...
Similar Trials
Recruiting
Phase 3
[18F]PI-2620 Phase 3 Histopathological StudyAlzheimer DiseaseNCT05641688Lantheus Biosciences Ltd.200
Completed
Phase 3
Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.Prostate Cancer RecurrentRecurrent Prostate CancerNCT04644822Centre for Probe Development and Commercialization100
Unknown
Phase 3
Immunotherapy With Racotumomab in Advanced Lung CancerLung Cancer, Non-small CellNSCLCNCT01460472Recombio SL1,082
Active, not recruiting
Phase 1
A Phase 3, Multicenter, Open-label, Rater-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline for the Treatment of Multibacillary Leprosy When Combined With Rifampicin and ClofazimineEUCTR2021-006613-10-Outside-EU/EEAJanssen Pharmaceutica NV
Recruiting
Phase 3
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal CancerColorectal Cancer MetastaticNCT06008119Shanghai Kechow Pharma, Inc.165
Related News
European Commission Grants Orphan Drug Designation to Florbetaben (18F) for ATTR Amyloidosis Diagnosis- Life Molecular Imaging's florbetaben (18F) has received orphan drug designation from the European Commission for diagnosing transthyretin (ATTR) amyloidosis, expanding its diagnostic applications beyond Alzheimer's disease.
- The radiotracer, originally approved for detecting brain amyloid plaques, is being evaluated in a Phase 3 trial to validate its efficacy in diagnosing cardiac amyloidosis using PET imaging.
- ATTR amyloidosis remains below the orphan disease threshold despite rising incidence rates, with fewer than five cases per ten thousand inhabitants in the general population.
- The designation supports development of improved diagnostic tools for a rare disease where early detection is crucial for accessing life-saving therapies.last yearFDA Grants Fast Track Designation to [18F]Florbetaben for Cardiac Amyloidosis Diagnosis- The FDA has granted Fast Track designation to [18F]florbetaben for diagnosing cardiac AL and ATTR amyloidosis, aiming to expedite its development and evaluation.
- [18F]florbetaben PET imaging has shown potential in identifying amyloid deposits in the heart and previously received orphan drug status for AL amyloidosis.
- An ongoing Phase 3 trial (NCT05184088) is evaluating [18F]florbetaben's efficacy in diagnosing cardiac amyloidosis compared to standard diagnostic methods.
- The Fast Track designation highlights [18F]florbetaben's potential to address a critical unmet need in the early and accurate diagnosis of cardiac amyloidosis.last yearLife Molecular Imaging Secures FDA Fast Track Designation for [18F]florbetaben in Cardiac Amyloidosis Diagnosis- Life Molecular Imaging received FDA Fast Track Designation for [18F]florbetaben to diagnose cardiac amyloid light-chain (AL) and amyloid transthyretin-related (ATTR) amyloidosis.
- The PET imaging agent is already approved as Neuraceq® for detecting brain amyloid plaques and has demonstrated capability to identify amyloid deposits in the heart.
- A Phase 3 trial (NCT05184088) is currently underway to validate [18F]florbetaben's efficacy in cardiac amyloidosis diagnosis.
- The designation aims to streamline the complex diagnostic process for cardiac AL amyloidosis, potentially providing earlier access to therapy and improved patient monitoring.8 years ago